Projects search

Publication in academic press/journals (14)

1. Physiologically Relevant Oxygen Concentration (6% O2) as an Important Component of the Microenvironment Impacting Melanoma Phenotype and Melanoma Response to Targeted Therapeutics In Vitro

   Authors:

   Osrodek M, Hartman ML, Czyz M

   Academic press:

   International Journal of Molecular Sciences (year: 2019, volume: 20, pages: E4203), Publisher: MDPI

   Status:

   Published

   DOI:

   10.3390/ijms20174203 – link to the publication

2. TYRP1 mRNA level is stable and MITF-M-independent in drug-naïve and vemurafenibresistant melanoma cells

   Authors:

   Hartman ML Czyz M

   Academic press:

   Archives of Dermatological Research (year: 2020, volume: 12, pages: 385-392), Publisher: Springer

   Status:

   Published

   DOI:

   10.1007/s00403-019-01995-w – link to the publication

3. Role of miRNAs in Melanoma Metastasis

   Authors:

   Anna Gajos-Michniewicz, Małgorzata Czyż

   Academic press:

   Cancers (year: 2019, volume: 11, pages: E326), Publisher: MDPI

   Status:

   Published

   DOI:

   10.3390/cancers11030326 – link to the publication

4. 17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAFV600E inhibitors in melanoma cells of different genetic subtypes.

   Authors:

   Mielczarek-Lewandowska A, Sztiller-Sikorska M, Osrodek M, Czyz M, Hartman ML

   Academic press:

   Apoptosis (year: 2019, volume: 24, pages: 596-611), Publisher: Springer

   Status:

   Published

   DOI:

   10.1007/s10495-019-01542-y – link to the publication

5. Fibroblast Growth Factor Receptor Signaling in Skin Cancers

   Authors:

   Czyz M

   Academic press:

   Cells (year: 2019, volume: 8, pages: E540), Publisher: MDPI

   Status:

   Published

   DOI:

   10.3390/cells8060540 – link to the publication

6. Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program

   Authors:

   Czyz M, Sztiller-Sikorska M, Gajos-Michniewicz A, Osrodek M, Hartman ML

   Academic press:

   Journal of Oncology (year: 2019, volume: 2019, pages: 1697913), Publisher: Hindawi

   Status:

   Published

   DOI:

   10.1155/2019/1697913 – link to the publication

7. Whole-exome sequencing reveals novel genetic variants associated with diverse phenotypes of melanoma cells

   Authors:

   Hartman ML, Sztiller-Sikorska M, Czyz M

   Academic press:

   Molecular Carcinogenesis (year: 2019, volume: 58, pages: 588-602), Publisher: Wiley

   Status:

   Published

   DOI:

   10.1002/mc.22953 – link to the publication

8. miRNAs in Melanoma: Tumor Suppressors and Oncogenes with Prognostic Potential.

   Authors:

   Wozniak M, Mielczarek A, Czyz M.

   Academic press:

   Current Medicinal Chemistry (year: 2016, volume: 23 (28), pages: 3136-3153), Publisher: Bentham Science Publishers

   Status:

   Published

9. Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity

   Authors:

   Mariusz L. Hartman, Malgorzata Sztiller-Sikorska, Anna Gajos-Michniewicz and Malgorzata Czyz

   Academic press:

   Cells (year: 2020, volume: 9, pages: 142), Publisher: MDPI

   Status:

   Published

   DOI:

   10.3390/cells9010142 – link to the publication

10. 17-Aminogeldanamycin Inhibits Constitutive Nuclear Factor-Kappa B (NF-κB) Activity in Patient-Derived Melanoma Cell Lines

    Authors:

    Hartman ML, Rogut M, Mielczarek-Lewandowska A, Wozniak M, Czyz M

    Academic press:

    International Journal of Molecular Sciences (year: 2020, volume: 21, pages: 3749), Publisher: MDPI

    Status:

    Published

    DOI:

    10.3390/ijms21113749 – link to the publication

11. Inhibitors of HSP90 in melanoma

    Authors:

    Aleksandra Mielczarek-Lewandowska, Mariusz L. Hartman, Malgorzata Czyz

    Academic press:

    Apoptosis (year: 2020, volume: 25, pages: 46384), Publisher: Springer

    Status:

    Published

    DOI:

    10.1007/s10495-019-01577-1 – link to the publication

12. HGF/c-MET Signaling in Melanocytes and Melanoma

    Authors:

    Czyz M

    Academic press:

    International Journal of Molecular Sciences (year: 2018, volume: 19 (12), pages: E3844), Publisher: MDPI

    Status:

    Published

    DOI:

    10.3390/ijms19123844 – link to the publication

13. Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of V600EBRAF melanoma cells and their response to vemurafenib and trametinib in vitro

    Authors:

    Zalesna I, Osrodek M, Hartman ML, Rozanski M, Sztiller-Sikorska M, Niewinna K, Nejc D, Czyz M

    Academic press:

    PlosOne (year: 2017, volume: 12 (8), pages: e0183498), Publisher: PLOS

    Status:

    Published

    DOI:

    10.1371/journal.pone – link to the publication

14. Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells

    Authors:

    Hartman ML, Rozanski M, Osrodek M, Zalesna I, Czyz M.

    Academic press:

    Laboratory Investigation (year: 2017, volume: 97(2), pages: 217-227), Publisher: Nature Publishing Group

    Status:

    Published

    DOI:

    10.1038/labinvest.2016.140. – link to the publication